Macquarie Group’s TherapeuticsMD TXMD Stock Holding History

Macquarie Group’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-987	Closed	-$37K	–	2647
2021 Q3	$37K	Buy	+987	New	+$43.8K	﹤0.01%	2320

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Macquarie Group's TXMD Position: Q4 2021 in Review

Macquarie Group sold out of TherapeuticsMD (TXMD) in Q4 2021, closing a stake of 987 shares — an estimated $37K sold.

Macquarie Group first reported a position in TXMD in Q3 2021 and held it in 1 quarter. The position peaked at $37K in Q3 2021. 131 funds tracked by Wall St. Rank hold TXMD as of Q4 2021.

Macquarie Group reported no remaining TherapeuticsMD position as of Q4 2021 after selling out during the quarter.
Macquarie Group sold 987 TherapeuticsMD shares in Q4 2021, an estimated $37K.
Macquarie Group first reported a position in TherapeuticsMD in Q3 2021 and held it in 1 quarter.
Macquarie Group's TherapeuticsMD position peaked at $37K in Q3 2021.
131 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2021.

Based on Macquarie Group's 13F filing for Q4 2021, filed 11 Feb 2022.